Crescent Biopharma (CBIO) Price & Analysis

Compare

990 Followers

CBIO Stock Chart & Stats

$13.13

Market closed

$13.13

Day’s Range― - ―

52-Week Range$9.81 - $63.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)145.41K

Market Cap

$172.82M

Enterprise Value$7.94M

Total Cash (Recent Filing)$133.26M

Total Debt (Recent Filing)$1.74M

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Apr 30, 2026

EPS EstimateN/A

Last Dividend Ex-Date

Jan 13, 2023

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.27

Shares Outstanding13,892,562

10 Day Avg. Volume163,515

30 Day Avg. Volume145,412

Financial Highlights & Ratios

PEG Ratio-24.58

Price to Book (P/B)-139.86

Price to Sales (P/S)0.00

P/FCF Ratio-51.61

Enterprise Value/Market Cap0.05

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.15

Forecast

1Y Price Target

$25.25

Price Target Upside92.31% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPositive results from the HARMONi-6 trial are likely to have significant positive implications for CR-001.

Market PotentialThe potential of PD-1 x VEGF bispecifics is validated across multiple disease settings, suggesting CBIO’s CR-001 could enter a large market with opportunities for expansion.

Pipeline DevelopmentCrescent's pipeline is on track for major value inflection, with CR-001 IND filing expected soon and POC data release anticipated as a major inflection point for the stock.

Bears Say

CompetitionThere are questions about the PD-1xVEGF class, and CR-001 is behind other PD-(L)1×VEGFs that are in later stages of clinical development.

Financial PerformanceCBIO reported a net loss of $24.6 million.

Crescent Biopharma News

Crescent Biopharma reports Q3 EPS ($1.27), two est. ($1.38)

“We have made exciting progress during 2025 advancing our pipeline of next generation therapeutics for solid tumors toward...

2d ago

CBIO

Crescent Biopharma to present preclinical data from CR-001

Crescent Biopharma (CBIO) announced that preclinical data from CR-001, its PD-1 x VEGF bispecific antibody being developed for...

4d ago

CBIO

Citizens JMP healthcare analysts hold an analyst/industry conference call

Analyst discuss the evolving landscape in Non-Small Cell Lung Cancer (NSCLC) (relevant companies SMMT TIL CBIO IMMP NVLT)...

29d ago

TIL

CBIO

Crescent Biopharma Advances Cancer Therapy Pipeline

Crescent Biopharma, Inc. ( ($CBIO) ) has released its Q3 earnings. Here is a breakdown of the information...

1d ago

CBIO

Crescent Biopharma’s Promising Pipeline and Strategic Progress Drive Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on CBIO stock, giving a Buy rating today....

2d ago

CBIO

Crescent Biopharma: Strategic Positioning and Promising Pipeline Justify Buy Rating

Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Crescent Biopharma, retaining the price target of...

2d ago

CBIO

Crescent Biopharma’s CR-001: Promising Efficacy and Market Potential Following HARMONi-A Study Success

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Crescent Biopharma. The associated price target...

2M ago

CBIO

Positive Outlook for Crescent Biopharma’s CR-001 Driven by Promising HARMONi-A Trial Results and Potential in NSCLC Treatment

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Crescent Biopharma and keeping the price target...

2M ago

CBIO

Crescent Biopharma initiated with a Buy at Jefferies

Jefferies initiated coverage of Crescent Biopharma (CBIO) with a Buy rating and $26 price target Crescent is a...

3M ago

CBIO

Crescent Biopharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Crescent Biopharma (CBIO) with a Buy rating and $25 price target The company’s...

3M ago

CBIO

Crescent Biopharma: Strategic Positioning and Promising Pipeline Drive Buy Rating

LifeSci Capital analyst Charles Zhu has maintained their bullish stance on CBIO stock, giving a Buy rating today....

3M ago

CBIO

Crescent Biopharma Approves Executive Severance Plan

Crescent Biopharma ( ($CBIO) ) has provided an update. On July 29, 2025, Crescent Biopharma‘s Board of Directors...

3M ago

CBIO

Crescent Biopharma reports Q2 EPS ($4.93)

“The second quarter of 2025 was momentous for Crescent. We bolstered our leadership team, completed our merger and...

3M ago

CBIO

Crescent Biopharma sees cash runway through 2027

Cash was $152.6 million as of June 30, 2025, which is anticipated to fund operations through 2027. Published...

3M ago

CBIO

CBIO FAQ

What was Crescent Biopharma’s price range in the past 12 months?

Crescent Biopharma lowest stock price was $9.81 and its highest was $63.00 in the past 12 months.

What is Crescent Biopharma’s market cap?

Crescent Biopharma’s market cap is $172.82M.

When is Crescent Biopharma’s upcoming earnings report date?

Crescent Biopharma’s upcoming earnings report date is Apr 30, 2026 which is in 173 days.

How were Crescent Biopharma’s earnings last quarter?

Crescent Biopharma released its earnings results on Nov 06, 2025. The company reported -$1.27 earnings per share for the quarter, beating the consensus estimate of -$1.959 by $0.689.

Is Crescent Biopharma overvalued?

According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Crescent Biopharma pay dividends?

Crescent Biopharma pays a Quarterly dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Crescent Biopharma dividends here

What is Crescent Biopharma’s EPS estimate?

Crescent Biopharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Crescent Biopharma have?

Crescent Biopharma has 13,892,562 shares outstanding.

What happened to Crescent Biopharma’s price movement after its last earnings report?

Crescent Biopharma reported an EPS of -$1.27 in its last earnings report, beating expectations of -$1.959. Following the earnings report the stock price went up 5.39%.

Which hedge fund is a major shareholder of Crescent Biopharma?

Currently, no hedge funds are holding shares in CBIO

Crescent Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-51.70%

Trailing 12-Months

Asset Growth

544.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Crescent Biopharma

Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.

Crescent Biopharma (CBIO) Earnings & Revenues

Historic Earnings Reports

CBIO Stock 12 Month Forecast

Average Price Target

$25.25

▲(92.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","18":"$18","25":"$25","32":"$32","39":"$39"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,18,25,32,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.75,13.923076923076923,15.096153846153847,16.26923076923077,17.442307692307693,18.615384615384617,19.78846153846154,20.96153846153846,22.134615384615387,23.307692307692307,24.480769230769234,25.653846153846153,26.826923076923077,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.75,13.711538461538462,14.673076923076923,15.634615384615385,16.596153846153847,17.557692307692307,18.51923076923077,19.48076923076923,20.442307692307693,21.403846153846153,22.365384615384613,23.326923076923077,24.28846153846154,{"y":25.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.75,13.461538461538462,14.173076923076923,14.884615384615385,15.596153846153847,16.307692307692307,17.01923076923077,17.73076923076923,18.442307692307693,19.153846153846153,19.865384615384617,20.576923076923077,21.28846153846154,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.61,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.58,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":38.26,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":32.94,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.9,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.82,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.18,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.11,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.2,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >